VOR vs LLY vs NVO vs BEAM vs EDIT

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 6. 4% for Novo Nordisk A/S (NVO). Novo Nordisk A/S (NVO) offers the better valuation at 12. 3x trailing P/E (2. 0x forward), making it the more compelling value choice. Analysts rate Vor Biopharma Inc. (VOR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

3x versus Eli Lilly and Company at 49. 4x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Eli Lilly and Company's 1. 07x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -96. 8% for Vor Biopharma Inc. (VOR). Over 10 years, the gap is even starker: LLY returned +1485% versus VOR's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

53β versus Editas Medicine, Inc. 's 2. 52β — meaning EDIT is approximately 378% more volatile than LLY relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 3% for Editas Medicine, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus 6. 4% for Novo Nordisk A/S (NVO). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -107. 4% for Vor Biopharma Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -395. 0% for Editas Medicine, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — EDIT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Eli Lilly and Company's 1. 07x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 0x forward P/E versus 30. 9x for Eli Lilly and Company — 28. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VOR: 120. 5% to $31. 67.

In this comparison, NVO (4.

1% yield), LLY (0. 5% yield) pay a dividend. VOR, BEAM, EDIT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, EDIT: -91. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VOR is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; NVO is a mid-cap deep-value stock; BEAM is a small-cap high-growth stock; EDIT is a small-cap high-growth stock. LLY, NVO pay a dividend while VOR, BEAM, EDIT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.